Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4835 - Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial.


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Cytotoxic Therapy;  Immunotherapy

Tumour Site

Colon and Rectal Cancer


Yasunori Emi


Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281


Y. Emi1, T. Yamanaka2, K. Muro3, H. Uetake4, E. Oki5, T. Takahashi6, Y. Katayose7, K. Yoshida6, M. Sakamoto8, S. Aishima9, K. Ishida10, J. Imura11, M. Unno12, I. Hyodo13, N. Tomita14, K. Sugihara4, Y. Maehara5

Author affiliations

  • 1 Surgery, Saiseikai Fukuoka General Hospital, 810 0001 - FUKUOKA/JP
  • 2 Department Of Biostatistics, Yokohama City University Hospital, 236-004 - Yokohama/JP
  • 3 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 4 Specialized Surgeries, Tokyo Medical and Dental University, Tokyo/JP
  • 5 Department Of Surgery And Science, Graduate School Of Medical Sciences, Kyushu University, Fukuoka/JP
  • 6 Surgical oncology, Gifu University Hospital, 501-1194 - Gifu/JP
  • 7 Surgery, Tohoku Rosai Hospital, 981-8563 - Sendai/JP
  • 8 Pathology, Keio University School of Medicine, Tokyo/JP
  • 9 Pathology And Microbiology, Saga University, Saga/JP
  • 10 Molecular Diagnostic Pathology, Iwate Medical University, Morioka/JP
  • 11 Diagnostic Pathology, University of Toyama, Toyama/JP
  • 12 Surgery, Tohoku University Hospital, 980-8575 - Sendai/JP
  • 13 Department Of Gastroenterology, University of Tsukuba, 305-8577 - Tsukuba/JP
  • 14 Surgery, Hyogo College of Medicine, 663-8501 - Nishinomiya/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4835


We previously reported the results of a randomized phase II controlled trial comparing mFOLFOX6 plus bevacizumab (Bmab) with mFOLFOX6 plus cetuximab (Cmab) for KRAS wild-type (wt) colorectal cancer (CRC) with liver-limited metastases that were not optimally resectable. The current study is the first to examine the role of histopathologic response based on the study data of anti-VEGF versus anti-EGFR antibody.


In the ATOM trial, KRAS wild-type CRC patients with liver-limited metastases were eligible if the number of lesions was more than 5 and/or the size of lesions was more than 5cm in the maximum diameter. The primary endpoint was progression-free survival (PFS). Of 116 eligible patients, patients who underwent liver metastasectomy were evaluated for histopathologic response in this study. Resected liver specimens were assessed by the independent pathological review committee. Preplanned pathological assessments included tumor regression grade (TRG), dangerous halo, and sinusoidal obstruction of resected liver specimens. Patients were categorized into major histopathologic response (MjHR) if they had TRG of 1 (viable tumor cells = 0%) or 2 (< 25%), partial histopathologic response (PHR) if they had TRG of 3 (< 50%), or no histopathologic response (NHR) if they had TRG of 4 (< 75%) or 5 (> 75%).


A total of 59 patients had TRG evaluation based on resected specimens by liver metastasectomy. Of those, 55 (28 in Bmab arm, 27 in Cmab arm) were eligible for analysis. In the Bmab arm, the number of patients with MjHR/PHR/NHR was 12/1/15 (43/4/54%); in the Cmab arm, 13/10/4 (48/37/15%). Median PFS of patients with a MjHR or PHR/NHR was 8.3 or 4.4 months in the Bmab arm and Not Reached or 5.4 months in the Cmab arm. Patients with a MjHR had a longer PFS than those with a PHR/NHR in both the Bmab arm (hazard ratio [HR], 0.50 (95%CI, 0.19-1.28)) and the Cmab arm (HR, 0.17 (95%CI, 0.05-0.58)).


In the TRG assessment, the proportion of MjHR was similar between the two arms. The impact of MjHR on PFS as compared to PHR/NHR was observed in both arms. Further results regarding other assessments will be presented.

Clinical trial identification


Legal entity responsible for the study

ATOM study group.


Chugai Pharmaceutical.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.